Primary Chemotherapy and Targeted Molecular Therapy of Epithelial Ovarian Cancer

2017 ◽  
pp. 207-224
Author(s):  
Satoru Nagase ◽  
Tsuyoshi Ohta ◽  
Manabu Seino
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Molecular Therapy ◽  
Primary Chemotherapy ◽  
Targeted Molecular Therapy

Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer

2011 ◽  
Vol 21 (9) ◽  
pp. 1573-1578 ◽  
Author(s):  
Johanna Hynninen ◽  
Annika Auranen ◽  
Kirsti Dean ◽  
Maija Lavonius ◽  
Olli Carpen ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Serum Biomarker ◽  
Primary Chemotherapy ◽  
Ca 125 ◽  
Chemotherapy Response ◽  
Primary Therapy ◽  
Response To Chemotherapy

ObjectiveHuman epididymis protein 4 (HE4) is a promising novel serum biomarker for the detection of early-stage epithelial ovarian cancer (EOC) and for the differential diagnosis between benign and malignant ovarian tumors. The objective of the present study was to determine the value of HE4 for monitoring the response to primary therapy in patients with advanced disease.MethodsSerum HE4 and cancer antigen (CA) 125 levels of 10 patients with advanced EOC and one patient with adenocarcinoma of unknown origin were measured preoperatively and during first-line chemotherapy. Seven patients were treated with primary surgery and six cycles of chemotherapy. Response to treatment was evaluated 4 weeks after the completion of chemotherapy using computed tomography. Four patients received neoadjuvant chemotherapy (NACT) before surgery. To evaluate the early response to chemotherapy, changes in serum biomarker levels were compared with metabolic changes of tumors during NACT as detected by positron emission tomography/computed tomography.ResultsThe profile of HE4 during primary chemotherapy was in line with radiologic and clinical responses. In the neoadjuvant chemotherapy group, HE4 correlated better with the radiologic response than CA 125.ConclusionAssessment of serum HE4 may improve the reliability of response evaluation during chemotherapy for serous epithelial ovarian cancer.

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer

2009 ◽  
Vol 114 (2) ◽  
pp. 242-245 ◽  
Author(s):  
Rodney P. Rocconi ◽  
Kellie S. Matthews ◽  
Meredith K. Kemper ◽  
Kelly E. Hoskins ◽  
Warner K. Huh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Primary Chemotherapy ◽  
Ca 125

Primary chemotherapy and maintenance therapy in epithelial ovarian cancer

2008 ◽  
Vol 1 (2) ◽  
pp. 99-102 ◽  
Author(s):  
A. G. Zeimet ◽  
D. Reimer ◽  
N. Concin ◽  
S. Braun ◽  
C. Marth
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Epithelial Ovarian Cancer ◽  
Primary Chemotherapy

Use of next generation sequencing to predict response to primary chemotherapy in epithelial ovarian cancer

2017 ◽  
Vol 145 ◽  
pp. 91
Author(s):  
E. Zantow ◽  
C.C. Gunderson ◽  
J.A. Elvin ◽  
L. Albacker ◽  
K.N. Moore ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Next Generation Sequencing ◽  
Epithelial Ovarian Cancer ◽  
Primary Chemotherapy ◽  
Next Generation ◽  
Generation Sequencing

The Clinical Impact of Computed Tomography Immediately Following Primary Chemotherapy in Patients With Epithelial Ovarian Cancer

2010 ◽  
Vol 3 (1) ◽  
pp. 52-55
Author(s):  
Jenny M. Whitworth ◽  
Kellie E. Schneider ◽  
Janelle M. Fauci ◽  
Amelia L. Sutton ◽  
Peter J. Frederick ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Impact ◽  
Primary Chemotherapy

Prediction of survival in patients with epithelial ovarian cancer based on the timing and rate of normalization of CA125 levels during primary chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5585-5585
Author(s):  
K. S. Matthews ◽  
R. P. Rocconi ◽  
M. Kemper ◽  
K. E. Hoskins ◽  
W. K. Huh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Eligible Patient ◽  
Primary Chemotherapy ◽  
Rank Test ◽  
Primary Therapy ◽  
Linear Regression Models ◽  
Platinum Sensitivity ◽  
Platinum Based Chemotherapy ◽  
Response To Chemotherapy

5585 Objective: CA125 is the tumor marker used to evaluate response to chemotherapy in patients with epithelial ovarian cancer (EOC). The aim of this study was to determine if the timing of normalization or percent decrease in CA125 levels during primary chemotherapy could predict survival. Methods: Patients treated at our institution for EOC with primary taxane/platinum-based chemotherapy for 6 cycles between 1996 and 2005 were eligible. Patient demographics, chemotherapy administration, CA125 levels, and survival outcomes were abstracted. Progression-free- survival (PFS), overall survival (OS), and platinum sensitivity (> 6 months from chemotherapy completion) were compared to CA125 levels during primary therapy. Baseline levels, change over time, and timing of CA125 normalization were calculated. Analyses were performed using Kaplan-Meier method and compared using the log-rank test, Chi-square test and Fischer’s exact test. Results: 269 patients with EOC were identified. When stratified by which cycle of chemotherapy achieved normalization, PFS ranged from 25 months at 1st cycle to 4 months at 6th cycle (p< 0.001). OS showed a similar benefit from 74 months at 1st cycle to 22 months at 6th cycle (p<0.001). Platinum sensitivity improved from 23% (normal CA125 after 6th cycle) to 72% (normal CA125 after 1st cycle) (p=0.003). Patients with normalization after the 3rd cycle or sooner compared to patients with normalization after the 4th cycle demonstrated improved PFS (19 vs. 6 months; p<0.001), OS (48 vs. 27 months; p=0.001) and platinum sensitivity (78 vs. 22%; p<0.001). Linear regression models of the slope of the decline of CA125 levels correlated with PFS (p=0.03); however, the models failed to predict an OS advantage. Conclusion: Earlier normalization of CA125 levels during primary chemotherapy for EOC predicts improvement in platinum sensitivity, PFS, and OS. This data provides prognostic information that may influence future decisions regarding chemotherapy. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document